- Home
- CADL vs ACHV Comparison
CADL vs ACHV Comparison
Compare CADL & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- ACHV
- Stock Information
- Founded
- CADL 1999
- ACHV N/A
- Country
- CADL United States
- ACHV Canada
- Employees
- CADL N/A
- ACHV N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CADL Health Care
- ACHV Health Care
- Exchange
- CADL Nasdaq
- ACHV Nasdaq
- Market Cap
- CADL 159.1M
- ACHV 149.6M
- IPO Year
- CADL 2021
- ACHV N/A
- Fundamental
- Price
- CADL $6.60
- ACHV $4.16
- Analyst Decision
- CADL Strong Buy
- ACHV Strong Buy
- Analyst Count
- CADL 1
- ACHV 5
- Target Price
- CADL $11.00
- ACHV $14.80
- AVG Volume (30 Days)
- CADL 8.6M
- ACHV 113.3K
- Earning Date
- CADL 11-14-2024
- ACHV 11-07-2024
- Dividend Yield
- CADL N/A
- ACHV N/A
- EPS Growth
- CADL N/A
- ACHV N/A
- EPS
- CADL N/A
- ACHV N/A
- Revenue
- CADL N/A
- ACHV N/A
- Revenue This Year
- CADL N/A
- ACHV N/A
- Revenue Next Year
- CADL N/A
- ACHV N/A
- P/E Ratio
- CADL N/A
- ACHV N/A
- Revenue Growth
- CADL N/A
- ACHV N/A
- 52 Week Low
- CADL $1.02
- ACHV $3.20
- 52 Week High
- CADL $14.60
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- CADL 55.49
- ACHV 38.34
- Support Level
- CADL $4.42
- ACHV $4.07
- Resistance Level
- CADL $7.28
- ACHV $4.66
- Average True Range (ATR)
- CADL 1.35
- ACHV 0.18
- MACD
- CADL 0.26
- ACHV -0.03
- Stochastic Oscillator
- CADL 22.48
- ACHV 22.23
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.